1. To study the mechanisms of SRSF1 oncogenic activity in cancer.
2. Modulating MNK2 alternative splicing as novel anti-cancer therapy.
3. To study the role of hnRNP A2/B1 in cancer development and progression.
4. To identify the splicing changes that occur during ovarian and pancreatic cancer progression and their contribution to the metastatic process.
5. To study the role of alternative splicing in regulating glucose metabolism and diabetes.
6. Developing new therapies for genetic diseases caused by nonsense mutations and unstable mRNA.
7. Developing specific splicing factor inhibitors (decoy oligonucleotides) as novel anti-cancer therapy.
8. Enhancing immunotherapy by splicing modulation.